Houston med school develops revolutionary mRNA vaccine for elephants

zoology biology

Baylor College of Medicine's Jessica Watts, Dr. Jerome Pollet, and Dr. Paul Ling with Tess. Photo by Jackelin Reyna/Houston Zoo

An innovative team from Baylor College of Medicine and Texas Children’s Hospital has worked with the Houston Zoo to develop a first-of-its-kind treatment for elephants, which has been administered to its first patient.

Tess, the beloved, 40-year-old matriarch of the Houston Zoo’s elephant herd, is recovering well after receiving the first-ever mRNA vaccine against elephant endotheliotropic herpesvirus (EEHV) 1A on Tuesday, June 18. The veterinary staff at the Houston Zoo will monitor Tess in the coming weeks to check her reaction and the efficacy of the vaccine.

EEHV 1A is a deadly infection for Asian Elephants. While generally benign in African Elephants, Asian Elephants can develop fatal hemorrhages. The fatality rate is a whopping 80 percent, making it one of the most serous threats to elephant populations outside of humans.

Anti-viral drugs have some effect on the disease, but two-thirds show no improvement. This has led to a search for a vaccine. For 15 years, the Houston Zoo and Dr. Paul Ling at Baylor College of Medicine’s Department of Virology and Microbiology have partnered to develop the drug. They have been helped by worldwide research from zoos and animal specialists, as well as graduate student Jessica Watts and Dr. Jeroen Pollet at Houston's Texas Children’s Hospital. The research has been funded by private donations, research partnerships, and grants.

Before being inoculated, the mRNA vaccine was exhaustively tested, with the dosage being extrapolated from data involving horses.

Houston Zoo veterinarians will periodically test Tess to see if she is developing the appropriate antibodies. If she is and there are no adverse reactions, the next step will be to administer the vaccine to the rest of the Houston herd. Many of these are Tess’s own children (Tucker, Tupelo, Tilly, and Teddy) and grandchildren (Winnie).

Should the vaccine prove effective, the doses will be made available worldwide to zoos and private elephant sanctuaries. It is likely to have a significant benefit on protecting and preserving the Asian Elephant population. As of January, there are fewer than 50,000 of the animas left in the wild. They are currently listed as endangered, and breeding programs and research done through the Houston Zoo are essential to keeping the animals from going extinct.

------

This article originally ran on CultureMap.

From Your Site Articles
A Houston health care company received the green light from the FDA to advance a treatment that's targeting a deadly cancer. Photo via Getty Images

Houston immunotherapy company achieves FDA designation for cancer-fighting vaccine

got the green light

The FDA has granted a Houston-based company a Fast Track designation.

Diakonos Oncology Corp. is a clinical-stage immuno-oncology company that has developed a unique dendritic cell vaccine, DOC1021. The vaccine targets glioblastoma multiforme (GBM), the most common and most lethal malignant brain tumor in adults. The aggressive tumors come with a life expectancy of about 15 months following diagnosis. About 7 percent of those diagnosed survive five years, while the 10-year outlook only sees a one-percent survival rate.

“The FDA’s decision acknowledges the potential of this new treatment approach for a very challenging disease,” Diakonos CEO Mike Wicks says in a press release. “Our protocol represents a first for cancer immunotherapy and could be viable for many types of cancers beyond GBM.”

FDA Fast Track designations are intended to expedite the haste with which drugs with early clinical promise are reviewed, likely taking them to market faster.

DOC1021 uses the body’s natural anti-viral immune response to fight GBM. The vaccine mimics viral infection with the patient’s cancer markers. Essentially, DOC1021 uses the body’s own natural ability to detect and eliminate infected cells.

The technology uses dendritic cells, white blood cells that are able to perceive threats, to its advantage. The unique cancer markers are loaded both internally and externally into the immune cells, just as they would simultaneously occur in a viral infection. The individualized treatment is administered through three precise injections that target deep cervical lymph node chains. By dosing this way, the immune responses are directed straight to the central nervous system.

The results have spoken for themselves: All of the patients who have tried the treatment have exceeded survival expectations. And just as importantly, DOC1021 appears to be extremely safe. No serious adverse effects have been reported.

“Because Phase I clinical trials are generally not statistically powered to demonstrate efficacy, detection of a statistically significant efficacy signal is very promising,” says William Decker, associate professor of immunology at Baylor College of Medicine and inventor of the DOC1021 technology.

The Phase 1 open-label trial of DOC1021 (NCT04552886) is currently taking place at both the University of Texas Health Science Center in Houston and at the MD Anderson Cancer Center at Cooper University Health Care in Camden, NJ. The trial is expected to complete this year.

Drs. Maria Elena Bottazzi and Peter Hotez got the green light to distribute their low-cost COVID-19 vaccine in Indonesia. Photo courtesy

Houston doctors get approval for low-cost COVID vaccine abroad

green light

A Houston-born COVID-19 vaccine has gotten the go-ahead to be produced and distributed in Indonesia.

PT Bio Farma, which oversees government-owned pharmaceutical manufacturers in Indonesia, says it’s prepared to make 20 million doses of the IndoVac COVID-19 vaccine this year and 100 million doses a year by 2024. This comes after the vaccine received authorization from the Indonesian Food and Drug Authority for emergency use in adults.

With more than 275 million residents, Indonesia is the world’s fourth most populous country.

IndoVac was created by the Texas Children’s Hospital Center for Vaccine Development and Baylor College of Medicine. Drs. Peter Hotez and Maria Elena Bottazzi lead the vaccine project. Bio Farma is licensing IndoVac from BCM Ventures, the commercial group at the Baylor College of Medicine.

“Access to vaccines in the developing world is critical to the eradication of this virus,” Hotez, co-director of the Texas Children’s Hospital Center for Vaccine Development and dean of the National School of Tropical Medicine at Baylor College of Medicine, says in a news release.

Aside from distributing the vaccine in Indonesia, Bio Farma plans to introduce it to various international markets.

“The need for a safe, effective, low-cost vaccine for middle- to low-income countries is central to the world’s fight against the COVID-19 pandemic,” says Bottazzi, co-director of the Texas Children’s Hospital Center for Vaccine Development and associate dean of the National School of Tropical Medicine at Baylor.

“Without widespread inoculation of populations in the developing world, which must include safe, effective booster doses, additional [COVID-19] variants will develop, hindering the progress achieved by currently available vaccines in the United States and other Western countries.”

Bio Farma says it has completed Phase 1 and Phase 2 clinical trials for IndoVac and is wrapping up a Phase 3 trial.

IndoVac is a version of the patent-free, low-cost Corbevax vaccine, developed in Houston and dubbed “The World’s COVID-19 Vaccine.” The vaccine formula can be licensed by a vaccine producer in any low- or middle-income country, which then can take ownership of it, produce it, name it, and work with government officials to distribute it, Hotez told The Texas Tribune in February.

Among donors that have pitched in money for development of the vaccine are the Houston-based MD Anderson and John S. Dunn foundations, the San Antonio-based Kleberg Foundation, and Austin-based Tito’s Vodka.

“During 2022, we hope to partner with the World Health Organization and other United Nations agencies to vaccinate the world. We believe that global vaccine equity is finally at hand and that it is the only thing that can bring the COVID pandemic to an end,” Hotez and Bottazzi wrote in a December 2021 article for Scientific American.

Drs. Maria Elena Bottazzi and Peter Hotez at the Center for Vaccine Development. Photo courtesy of Texas Children's Hospital

2 Houston powerhouses deploy game-changing COVID-19 worldwide vaccine

a good shot

With the U.S. logging its highest single-day total of new COVID-19 cases (441,278 infections) and some 281, 808, 270 cases documented worldwide, new treatments worldwide are in major demand — especially in emerging nations.

To that end, Texas Children’s Hospital and Baylor College of Medicine announced a new COVID vaccine ready to deploy in India and soon, other underserved countries.

Corbevax, which is dubbed “The World’s COVID-19 Vaccine,” utilizes a traditional recombinant protein-based technology that will enable production at large scales, per a press release. That means the inoculation will be widely accessible to inoculate the global population.

This new vaccine was developed at Texas Children’s Hospital CVD and led by co-directors Drs. Maria Elena Bottazzi and Peter Hotez — and in-licensed from BCM Ventures, Baylor College of Medicine’s integrated commercialization team, to Hyderabad-based vaccine and pharmaceutical company Biological E. Limited (BE).

After completing two Phase III clinical trials involving more than 3000 subjects the vaccine was found to be safe, well tolerated, and immunogenic. Current research shows Corbevax notably effective against the Ancestral-Wuhan strain and the globally dominant Delta variant, press materials note.

Safe, streamlined, low-cost vaccines for middle- to low-income countries are central to the world’s fight against the COVID-19 pandemic, the two Houston organizations note. Indeed, without widespread vaccination of populations in the Global South, additional virus variants will arise, hindering the progress achieved by currently available vaccines in the United States and other Western countries, per research.

“This announcement is an important first step in vaccinating the world and halting the pandemic,” said Hotez in a statement. “Our vaccine technology offers a path to address an unfolding humanitarian crisis, namely the vulnerability the low- and middle-income countries face against the delta variant. Widespread and global vaccination with our Texas Children’s-Baylor-BE vaccine would also forestall the emergence of new variants. We have previously missed that opportunity for the alpha and delta variant. Now is our chance to prevent a new global wave from what might follow.”

------

This article originally ran on CultureMap.

Texas Children's Hospital and Baylor College of Medicine are working on a new COVID-19 vaccine candidate. Photo by Dwight C. Andrews/Greater Houston Convention and Visitors Bureau

Houston health care organizations team up for the 'people's vaccine'

COVID Collaboration

Two major health care institutions in Houston — Texas Children's Hospital and the Baylor College of Medicine — are a step closer to rolling out what they dub the "people's vaccine" for COVID-19.

The two institutions, along with India-based vaccine and pharmaceutical company Biological E Ltd., have gained approval to move ahead this month with Phase III clinicals trials in India of a COVID-19 vaccine candidate called Corbevax. The Texas Children's Hospital Center for Vaccine Development developed the vaccine's protein antigen, which was licensed from the Baylor College of Medicine's BCM Ventures commercialization arm.

Unlike COVID-19 vaccines in the U.S., Corbevax contains the so-called "spike protein" from the surface of the novel coronavirus. Once that protein is injected via a vaccine, the body is supposed to begin building immunity against the protein and thereby prevent serious illness.

Experts envision Corbevax being a readily available weapon in the global fight against the COVID-19 pandemic, thanks to the simple vaccine platform (like the one used to prevent Hepatitis B) and the ability to store the vaccine in normal refrigerated settings. The targets of this vaccine are children and mothers.

"In the midst of India's public health crisis, it is our hope that our Texas Children's and Baylor COVID-19 vaccine can be released for emergency authorization in India and in all countries in need of essential COVID-19 vaccinations," Dr. Peter Hotez, co-director of the Texas Children's Hospital Center for Vaccine Development, says in a June 9 news release.

India has reported more than 29 million cases of COVID-19, causing 354,000 deaths. The country's COVID-19 surge reached its peak in May.

"The vaccines currently available cannot be manufactured quick enough to meet supply shortages in low-income countries," Hotez says. "Our vaccine is truly 'the people's vaccine,' created to serve the most marginalized and underserved populations that are hardest hit by this pandemic. This is the vaccine that could be used to vaccinate the world."

In the Phase III trial, the two-dose Corbevax vaccine will be administered to about 1,200 people age 18 to 80 at 15 sites in India. A larger global study of Corbevax is in the works.

According to India.com, Corbevax could be the most affordable COVID-19 vaccine available in the nation of nearly 1.37 billion people, costing close to $7 for a two-dose regimen. The Indian government already has preordered 300 million doses of Corbevax, which has shown promise in Phase I and Phase II trials. The Phase II trial ended in April.

If the Phase III trial goes as planned, doses could be widely administered as soon as August. Biological E initially plans to produce 75 million to 80 million doses per month, according to media reports. The Indian company foresees manufacturing at least 1 billion doses by the end of 2022.

ClassPass, which recently opened a Houston location, has launched a new tool for users to find their closest vaccine location. Photo courtesy of ClassPass

Tech company launches COVID-19 vaccine finder in Houston

there's an app for that

A global tech company that recently opened a local office in Houston has announced a major upgrade to its app — and it's now available in Houston.

ClassPass, a network of fitness and wellness partners, now has Houston vaccine centers searchable within the app and website. Members can find their closest vaccine center and get important information — like hours and address — as well as how to contact the locations; however, users aren't able to book directly through ClassPass.

"We are in a global health crisis and every company should be helping to support relief and vaccination efforts however they can. Using the ClassPass platform to connect members with vaccine centers is a natural extension of our technology and a way that we can contribute to curbing the spread of COVID-19," says Jeff Bladt, vice president of pricing and inventory, in a news release.

"We have deep knowledge of how to help people find accurate and up-to-date information on local businesses after routing millions of users to fitness and wellness locations across 30 countries," he adds.

Users can search for COVID vaccine locations online or through the app. Photo courtesy of ClassPass

The new search option has been rolled out already in in Austin and Dallas, as well as Boston, Chicago, Denver, Miami, New York City and Washington, D.C.

"The process of finding a vaccination appointment can be challenging and many people don't know where to start," says Dr. Vin Gupta, a critical care pulmonologist, health policy expert, and NBC News Medical Analyst, in the release.

"I was thrilled to hear that ClassPass, a high touch app that has already trained people how to search for vital health information, is leveraging their platform to make it easier to identify vaccine sites and secure appointments," he continues. "Anything that can address this information gap is critical in getting more people vaccinated."

ClassPass quickly pivoted when the pandemic hit last year, and now all 41,500 fitness, wellness, and beauty partners on the app have been asked to provide updated details on their COVID policies. ClassPass also worked with 5,000 top studios around the world to add digital classes as an option.

In March, Houston-based ClassPass exec, Rachel Moctron, joined the Houston Innovators Podcast to discuss this pivot and the new Houston office. Listen to it below.


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Texas university to lead new FAA tech center focused on drones

taking flight

The Texas A&M University System will run the Federal Aviation Administration’s new Center for Advanced Aviation Technologies, which will focus on innovations like commercial drones.

“Texas is the perfect place for our new Center for Advanced Aviation Technologies,” U.S. Transportation Secretary Sean Duffy said in a release. “From drones delivering your packages to powered lift technologies like air taxis, we are at the cusp of an aviation revolution. The [center] will ensure we make that dream a reality and unleash American innovation safely.”

U.S. Sen. Ted Cruz, a Texas Republican, included creation of the center in the FAA Reauthorization Act of 2024. The center will consist of an airspace laboratory, flight demonstration zones, and testing corridors.

Texas A&M University-Corpus Christi will lead the initiative, testing unstaffed aircraft systems and other advanced technologies. The Corpus Christi campus houses the Autonomy Research Institute, an FAA-designated test site. The new center will be at Texas A&M University-Fort Worth.

The College Station-based Texas A&M system says the center will “bring together” its 19 institutions, along with partners such as the University of North Texas in Denton and Southern Methodist University in University Park.

According to a Department of Transportation news release, the center will play “a pivotal role” in ensuring the safe operation of advanced aviation technologies in public airspace.

The Department of Transportation says it chose the Texas A&M system to manage the new center because of its:

  • Proximity to major international airports and the FAA’s regional headquarters in Fort Worth
  • Existing infrastructure for testing of advanced aviation technologies
  • Strong academic programs and industry partnerships

“I’m confident this new research and testing center will help the private sector create thousands of high-paying jobs and grow the Texas economy through billions in new investments,” Cruz said.

“This is a significant win for Texas that will impact communities across our state,” the senator added, “and I will continue to pursue policies that create new jobs, and ensure the Lone Star State continues to lead the way in innovation and the manufacturing of emerging aviation technologies.”

Texas Republicans are pushing to move NASA headquarters to Houston

space city

Two federal lawmakers from Texas are spearheading a campaign to relocate NASA’s headquarters from Washington, D.C., to the Johnson Space Center in Houston’s Clear Lake area. Houston faces competition on this front, though, as lawmakers from two other states are also vying for this NASA prize.

With NASA’s headquarters lease in D.C. set to end in 2028, U.S. Sen. Ted Cruz, a Texas Republican, and U.S. Rep. Brian Babin, a Republican whose congressional district includes the Johnson Space Center, recently wrote a letter to President Trump touting the Houston area as a prime location for NASA’s headquarters.

“A central location among NASA’s centers and the geographical center of the United States, Houston offers the ideal location for NASA to return to its core mission of space exploration and to do so at a substantially lower operating cost than in Washington, D.C.,” the letter states.

Cruz is chairman of the Senate Committee on Commerce, Science, and Transportation; and Babin is chairman of the House Committee on Science, Space, and Technology. Both committees deal with NASA matters. Twenty-five other federal lawmakers from Texas, all Republicans, signed the letter.

In the letter, legislators maintain that shifting NASA’s headquarters to the Houston area makes sense because “a seismic disconnect between NASA’s headquarters and its missions has opened the door to bureaucratic micromanagement and an erosion of [NASA] centers’ interdependence.”

Founded in 1961, the $1.5 billion, 1,620-acre Johnson Space Center hosts NASA’s mission control and astronaut training operations. More than 12,000 employees work at the 100-building complex.

According to the state comptroller, the center generates an annual economic impact of $4.7 billion for Texas, and directly and indirectly supports more than 52,000 public and private jobs.

In pitching the Johnson Space Center for NASA’s HQ, the letter points out that Texas is home to more than 2,000 aerospace, aviation, and defense-related companies. Among them are Elon Musk’s SpaceX, based in the newly established South Texas town of Starbase; Axiom Space and Intuitive Machines, both based in Houston; and Firefly Aerospace, based in the Austin suburb of Cedar Park.

The letter also notes the recent creation of the Texas Space Commission, which promotes innovation in the space and commercial aerospace sectors.

Furthermore, the letter cites Houston-area assets for NASA such as:

  • A strong business environment.
  • A low level of state government regulation.
  • A cost of living that’s half of what it is in the D.C. area.

“Moving the NASA headquarters to Texas will create more jobs, save taxpayer dollars, and reinvigorate America’s space agency,” the letter says.

Last November, NASA said it was hunting for about 375,000 to 525,000 square feet of office space in the D.C. area to house the agency’s headquarters workforce. About 2,500 people work at the agency’s main offices. NASA’s announcement set off a scramble among three states to lure the agency’s headquarters.

Aside from officials in Texas, politicians in Florida and Ohio are pressing NASA to move its headquarters to their states. Florida and Ohio both host major NASA facilities.

NASA might take a different approach, however. “NASA is weighing closing its headquarters and scattering responsibilities among the states, a move that has the potential to dilute its coordination and influence in Washington,” Politico reported in March.

Meanwhile, Congressional Delegate Eleanor Holmes Norton, a Democrat who represents D.C., introduced legislation in March that would prohibit relocating a federal agency’s headquarters (including NASA’s) away from the D.C. area without permission from Congress.

“Moving federal agencies is not about saving taxpayer money and will degrade the vital services provided to all Americans across the country,” Norton said in a news release. “In the 1990s, the Bureau of Land Management moved its wildfire staff out West, only to move them back when Congress demanded briefings on new wildfires.”

Houston research breakthrough could pave way for next-gen superconductors

Quantum Breakthrough

A study from researchers at Rice University, published in Nature Communications, could lead to future advances in superconductors with the potential to transform energy use.

The study revealed that electrons in strange metals, which exhibit unusual resistance to electricity and behave strangely at low temperatures, become more entangled at a specific tipping point, shedding new light on these materials.

A team led by Rice’s Qimiao Si, the Harry C. and Olga K. Wiess Professor of Physics and Astronomy, used quantum Fisher information (QFI), a concept from quantum metrology, to measure how electron interactions evolve under extreme conditions. The research team also included Rice’s Yuan Fang, Yiming Wang, Mounica Mahankali and Lei Chen along with Haoyu Hu of the Donostia International Physics Center and Silke Paschen of the Vienna University of Technology. Their work showed that the quantum phenomenon of electron entanglement peaks at a quantum critical point, which is the transition between two states of matter.

“Our findings reveal that strange metals exhibit a unique entanglement pattern, which offers a new lens to understand their exotic behavior,” Si said in a news release. “By leveraging quantum information theory, we are uncovering deep quantum correlations that were previously inaccessible.”

The researchers examined a theoretical framework known as the Kondo lattice, which explains how magnetic moments interact with surrounding electrons. At a critical transition point, these interactions intensify to the extent that the quasiparticles—key to understanding electrical behavior—disappear. Using QFI, the team traced this loss of quasiparticles to the growing entanglement of electron spins, which peaks precisely at the quantum critical point.

In terms of future use, the materials share a close connection with high-temperature superconductors, which have the potential to transmit electricity without energy loss, according to the researchers. By unblocking their properties, researchers believe this could revolutionize power grids and make energy transmission more efficient.

The team also found that quantum information tools can be applied to other “exotic materials” and quantum technologies.

“By integrating quantum information science with condensed matter physics, we are pivoting in a new direction in materials research,” Si said in the release.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

View All Listings